Cambrian Biopharma
VC Fund
New York, United States
Cambrian Biopharma is a VC fund in New York focused on Biotechnology and Biopharma. Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is todevelop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Cambrian Biopharma invests in
Stages Cambrian Biopharma invests in
Countries Cambrian Biopharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 5 (63%)
- Biopharma 3 (38%)
- Life Science 3 (38%)
- Medical 2 (25%)
- Health Care 2 (25%)
Stage
- Series A 3 (38%)
- Seed 2 (25%)
- Series B 2 (25%)
- Series C 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dennis Yamashita
Executive Vice President, Chemistry
|
Executive Vice President, Chemistry | Total investments: 0 | Find email | |
Adrienne Hallett
Vice-President of Global Policy
|
Vice-President of Global Policy | Total investments: 0 | Find email | |
Christian Angermayer
Co-Founder
|
Co-Founder | Total investments: 47 | Find email | |
Daisy Robinton
Scientist in Residence
|
Scientist in Residence | Total investments: 0 | Find email | |
James Peyer
Founder and CEO
|
Founder and CEO | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Amplifier Therapeutics is a biopharmaceutical firm, developing AMP-activated protein kinase (AMPK) activator molecules to treat aging-related disorders such as metabolic problems, cardiovascular diseases, kidney diseases, and cancer. | $33.3M / Series A / Oct 17, 2023 | ||
| Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $31M / Series B / Oct 12, 2022 | ||
| Oviva Therapeutics is a movement to improve women's experience of aging through biomedical research, development and advocacy. | $11.5M / Seed / May 19, 2022 | ||
| Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $32M / Series A / Jun 23, 2021 | ||
| Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we arecommitted to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. | $115M / Series C / Apr 13, 2021 | ||
| Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $30M / Series B / Jan 11, 2021 | ||
| Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery ofmedicines that alter the treatment landscape and contributing value to patients and society.Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA. | $28.5M / Series A / Oct 07, 2020 | ||
| Samsara Therapeutics, Inc. is an R&D-stage biopharmaceutical platform company aiming to discover, develop and commercialize therapeutics for the treatment of unmet medical needs and age-related diseases. Samsara's platform is a pipeline for the identification, chemical optimization, and in vivo validation of compounds that extend a healthylifespan. | $3.2M / Seed / Dec 20, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cambrian Biopharma invest in?
Cambrian Biopharma invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cambrian Biopharma?
Public channels for Cambrian Biopharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cambrian Biopharma?
The team at Cambrian Biopharma includes Dennis Yamashita (Executive Vice President, Chemistry), Adrienne Hallett (Vice-President of Global Policy) and Christian Angermayer (Co-Founder), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
